Sonnet BioTherapeutics Holdings, Inc. announces stockholder approval of proposed business combination with Hyperliquid Strategies Inc. The final voting results for the special meeting will be filed in a Form 8-K with the U.S. Securities and Exchange Commission.


Sonnetbio •
Revision history
6 recorded changes
Want your article here?
Promote with Leviathan News


